Identification of a lipid metabolism-related gene for cancer immunotherapy

Xin Jiang1, Wenqi Du1,2, Ce Shi3

  • 1Department of Pathology, Xuzhou Medical University, Xuzhou, China.

PubMed

Insights

Carnitine palmitoyltransferase-2 (CPT2) impacts anti-tumor immunity by influencing the tumor microenvironment and immune cell infiltration. High CPT2 expression correlates with better survival in cancer patients undergoing immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Metabolism

Background:

  • Tumors evade immune surveillance via multiple mechanisms.
  • Altered lipid metabolism in cancer cells affects anti-tumor immunity.
  • Few studies explore lipid metabolism genes in cancer immunotherapy.

Purpose of the Study:

  • Investigate the role of carnitine palmitoyltransferase-2 (CPT2) in anti-tumor immunity.
  • Determine CPT2's potential as a biomarker for cancer immunotherapy efficacy.

Main Methods:

  • Screened TCGA database for lipid metabolism genes.
  • Analyzed CPT2 gene expression, clinicopathological features, and protein interactions.
  • Assessed the relationship between CPT2 expression and patient survival.

Main Results:

  • CPT2 is crucial in tumor microenvironment and immune response pathways.
  • Increased CPT2 expression enhances tumor immune cell infiltration.
  • High CPT2 expression correlates with improved overall survival and prognosis in cancer patients.

Conclusions:

  • CPT2 plays a significant role in the tumor immune microenvironment.
  • CPT2 may serve as a predictive biomarker for cancer immunotherapy.
  • Further research on CPT2 could advance cancer immunotherapy development.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K